CF
TSHA icon

Corebridge Financial’s Taysha Gene Therapies TSHA Stock Holding History

Corebridge Financial’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-85,878
Closed -$119K – 2592
2025
Q1 		$119K Sell
85,878
-1,272
-1% -$2.13K ﹤0.01% 2355
2024
Q4 		$151K Sell
87,150
-4,948
-5% -$10.3K ﹤0.01% 2336
2024
Q3 		$185K Buy
92,098
+6,040
+7% +$13.3K ﹤0.01% 2267
2024
Q2 		$194K Buy
+86,058
New +$250K ﹤0.01% 2216

Other funds holding TSHA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Corebridge Financial's TSHA Position: Q2 2025 in Review

Corebridge Financial sold out of Taysha Gene Therapies (TSHA) in Q2 2025, closing a stake of 85,878 shares — an estimated $119K sold.

Corebridge Financial first reported a position in TSHA in Q2 2024 and held it in 4 quarters. The position peaked at $194K in Q2 2024. 150 funds tracked by Wall St. Rank hold TSHA as of Q2 2025.

  • Corebridge Financial reported no remaining Taysha Gene Therapies position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 85,878 Taysha Gene Therapies shares in Q2 2025, an estimated $119K.
  • Corebridge Financial first reported a position in Taysha Gene Therapies in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Taysha Gene Therapies position peaked at $194K in Q2 2024.
  • 150 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.